Oxycodone Hydrochloride Market Report 2026

The oxycodone hydrochloride market size has grown steadily in recent years. It will grow from $4.32 billion in 2025 to $4.49 billion in 2026 at a compound annual growth rate (CAGR) of 4%. The growth in the historic period can be attributed to increasing prevalence of chronic pain conditions, widespread use of opioids in post-surgical care, limited availability of alternative pain therapies, strong hospital-based prescribing practices, established oral opioid formulations.

The oxycodone hydrochloride market size is expected to see steady growth in the next few years. It will grow to $5.18 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to development of abuse-deterrent and tamper-resistant formulations, growing focus on controlled and regulated opioid use, expansion of generic drug manufacturing, rising cancer incidence and palliative care demand, innovation in pain management delivery systems. Major trends in the forecast period include rising demand for effective pain management therapies, growing use of extended release and abuse-deterrent formulations, increasing prescriptions for post-surgical and cancer-related pain, shift toward generic and cost-effective opioid formulations, strengthening regulatory oversight and controlled distribution.

The rising prevalence of chronic pain is anticipated to drive the growth of the oxycodone hydrochloride market in the coming years. Chronic pain, defined as pain lasting for three months or longer, significantly affects patients’ quality of life and contributes to increasing demand for effective pain management solutions. The growth in chronic pain cases is mainly linked to factors such as obesity, an aging population, and musculoskeletal conditions, which raise the incidence of disorders including osteoarthritis and lower back pain. Oxycodone hydrochloride aids in chronic pain management by acting on pain receptors within the nervous system, delivering relief from moderate to severe pain and enhancing patient comfort and daily functioning. For instance, in November 2024, according to the U.S. National Center for Health Statistics (NCHS), a US-based federal agency, 24.3% of adults in the United States experienced chronic pain, while 8.5% reported high-impact chronic pain that restricts daily life or work activities. Therefore, the increasing prevalence of chronic pain is fueling the growth of the oxycodone hydrochloride market.

Major companies operating in the oxycodone hydrochloride market are increasingly concentrating on the development of advanced formulations, such as combination therapies, to improve pain management outcomes while minimizing the risks associated with opioid dependence. Combination therapies involve the use of two or more medications together to enhance therapeutic effectiveness, address multiple pain pathways, or reduce adverse effects. For example, in April 2025, Elite Pharmaceuticals Inc., a US-based pharmaceutical company, introduced a generic version of Percocet (oxycodone hydrochloride and acetaminophen tablets, USP CII). This combination product is offered in multiple strengths and is indicated for the management of moderate to moderately severe pain, combining the strong analgesic effect of oxycodone with acetaminophen to enhance overall pain relief. As a Schedule II controlled substance, it has a high potential for abuse and dependence, necessitating careful medical oversight.

In June 2024, Elite Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Nostrum Laboratories Inc. to acquire three approved abbreviated new drug applications (ANDAs) for generic versions of Norco, Percocet, and Dolophine. Through this collaboration, the companies aim to broaden their portfolio of generic opioid analgesics, strengthen their position in the pain management market, and increase the availability of cost-effective alternatives to branded pain medications. Nostrum Laboratories Inc. is a US-based pharmaceutical company that manufactures prescription products, including formulations that combine oxycodone hydrochloride and acetaminophen.

Major companies operating in the oxycodone hydrochloride market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Purdue Pharma L.P., Alvogen Inc., Camber Pharmaceuticals, Noramco Inc., Rhodes Pharmaceuticals L.P., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Mylan N.V., Cipla Ltd., Torrent Pharmaceuticals Ltd., Sandoz International GmbH, Pfizer Inc., Novartis AG, Accord Healthcare Ltd., Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG.

North America was the largest region in the oxycodone hydrochloride market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oxycodone hydrochloride market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oxycodone hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the oxycodone hydrochloride market by increasing costs associated with imported active pharmaceutical ingredients and specialized manufacturing equipment. Product segments such as extended release tablets and capsules are more impacted due to complex production requirements, with North America and parts of Asia-Pacific experiencing notable cost pressures. These tariffs have contributed to higher pricing and supply chain adjustments. However, they have also encouraged domestic API production, strengthened local manufacturing capabilities, and supported long-term supply security.

The oxycodone hydrochloride market research report is one of a series of new reports that provides oxycodone hydrochloride market statistics, including oxycodone hydrochloride industry global market size, regional shares, competitors with a oxycodone hydrochloride market share, detailed oxycodone hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the oxycodone hydrochloride industry. This oxycodone hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oxycodone hydrochloride is a strong opioid analgesic used for the management of moderate to severe pain. It acts by binding to opioid receptors in the brain and spinal cord, thereby decreasing the perception of pain. It is widely prescribed for pain control following surgery or injury, as well as for chronic pain conditions.

The main product forms of oxycodone hydrochloride include extended-release tablets, immediate-release tablets, oral solutions, and extended-release capsules. Extended-release tablets are formulated to gradually release the active ingredient over an extended period, helping to maintain stable drug levels and reduce the need for frequent dosing. Oxycodone hydrochloride is administered via oral and parenteral routes and is commonly used in pain management, including post-surgical pain and cancer-related pain. The product is distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and it is used by end users including hospitals, clinics, and homecare settings.

The oxycodone hydrochloride market consists of sales of oxycodone injectable formulations, oxycodone nasal sprays, oxycodone suppositories, and percocet. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.